Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $8.12

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned an average rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.1250.

A number of equities analysts have weighed in on REPL shares. Cantor Fitzgerald lowered Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Finally, JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price objective for the company in a report on Friday, June 26th.

Insider Buying and Selling

In other news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC boosted its stake in Replimune Group by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after purchasing an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Replimune Group by 4.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after acquiring an additional 1,712 shares during the period. Ballentine Partners LLC lifted its position in Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after purchasing an additional 1,721 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after buying an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC boosted its position in Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after purchasing an additional 2,192 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Trading Down 0.1%

Shares of Replimune Group stock opened at $11.11 on Friday. The company’s 50-day moving average price is $7.85 and its 200-day moving average price is $7.37. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. Replimune Group has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a market cap of $932.57 million, a price-to-earnings ratio of -3.29 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities analysts expect that Replimune Group will post -2.25 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.